MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

20.83 0.58

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

20.61

Max

20.95

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

89.037

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-8.52% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.18%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

42M

410M

Iepriekšējā atvēršanas cena

20.25

Iepriekšējā slēgšanas cena

20.83

Ziņu noskaņojums

By Acuity

50%

50%

158 / 352 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. janv. 18:41 UTC

Peļņas

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

2026. g. 23. janv. 22:30 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. janv. 22:30 UTC

Tirgus saruna

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

2026. g. 23. janv. 22:03 UTC

Peļņas

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026. g. 23. janv. 21:52 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

2026. g. 23. janv. 21:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 23. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 23. janv. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 23. janv. 21:39 UTC

Peļņas

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

2026. g. 23. janv. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

2026. g. 23. janv. 21:12 UTC

Peļņas

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

2026. g. 23. janv. 20:31 UTC

Peļņas

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026. g. 23. janv. 20:12 UTC

Tirgus saruna

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

2026. g. 23. janv. 20:07 UTC

Tirgus saruna

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

2026. g. 23. janv. 19:36 UTC

Tirgus saruna

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

2026. g. 23. janv. 19:30 UTC

Tirgus saruna
Peļņas

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

2026. g. 23. janv. 19:18 UTC

Tirgus saruna

Gold and Silver Step Up to More Records -- Market Talk

2026. g. 23. janv. 19:15 UTC

Peļņas

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

2026. g. 23. janv. 18:53 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

2026. g. 23. janv. 18:21 UTC

Peļņas

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

2026. g. 23. janv. 18:19 UTC

Tirgus saruna

Intel Seen as Increasingly Confident on Demand -- Market Talk

2026. g. 23. janv. 17:59 UTC

Peļņas

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

2026. g. 23. janv. 17:57 UTC

Tirgus saruna

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

2026. g. 23. janv. 17:57 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. janv. 17:34 UTC

Tirgus saruna
Peļņas

Intel's Supply Challenges Seen Benefiting AMD -- Market Talk

2026. g. 23. janv. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 23. janv. 17:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 23. janv. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 23. janv. 17:13 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-8.52% uz leju

Prognoze 12 mēnešiem

Vidējais 19 USD  -8.52%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

158 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat